CTOs on the Move

SomaLogic

www.somalogic.com

 
Revolutionizing Proteomics To Transform Healthcare SomaLogic was founded in 2000 with the goal of improving the well-being and quality of life of every individual by transforming how diseases were detected and diagnosed. Building on the previous decade of aptamer research, SomaLogic scientists have developed a new proteomics technology that overcomes the significant challenges of current technologies, and which has multiple applications across the biological and medical sciences. Our mission is to leverage our proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Jim Covington
Vice President, Information Security and Privacy Profile
Jason Cleveland
Chief Technology Officer Profile
Greg Sparks
Chief Information Officer Profile

Funding

SomaLogic raised $81M on 12/22/2020

Similar Companies

Day One Biopharmaceuticals

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.

Fastgen Corporation

Fastgen Corporation is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opus Genetics

Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness`s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases.

Verdezyne

Verdezyne, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Interpace Biosciences

Interpace Biosciences is a company that provides molecular and related first line diagnostic tests for evaluating risk of cancer, as well as specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted...